{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:32:14Z","timestamp":1780407134015,"version":"3.54.1"},"reference-count":4,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Emerg Medicine Australasia"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Vitamin B17 tablets are sold (online) as an alternative cancer therapy medication. Its use however is not benign, given that it is metabolised into hydrogen cyanide. We aimed to measure the number of calls received by the New South Wales Poisons Information Centre (NSW PIC) regarding Amygdalin exposures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review of all amygdalin\/cyanogenic glycoside product ingestion exposure calls to NSW PIC between 2015 and 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 120 unique exposure calls. Eighty\u2010two (68%) were regarding minor exposures, with the remaining 38 (32%) of calls involving patients who had either a signifcant history or symptoms to prompt referral to hospital or were already seeking advice from a treating hospital clinican.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is a significant burden of concern generated from the misuse of cyanogenic glycoside products for cancer prevention and treatment, which can result in hospital admission carrying significant health risk and expenditure.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1742-6723.14450","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T06:59:00Z","timestamp":1716965940000},"page":"650-651","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u2018Vitamin <scp>B17<\/scp>\u2019: Killing more than cancer"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-2693","authenticated-orcid":false,"given":"Ingrid","family":"Berling","sequence":"first","affiliation":[{"name":"NSW Poisons Information Centre Sydney Children's Hospitals Network  Sydney New South Wales Australia"},{"name":"Department of Clinical Toxicology and Pharmacology Calvary Mater Newcastle  Newcastle New South Wales Australia"},{"name":"School of Medicine and Public Health The University of Newcastle  Newcastle New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6855-3865","authenticated-orcid":false,"given":"Jared","family":"Brown","sequence":"additional","affiliation":[{"name":"NSW Poisons Information Centre Sydney Children's Hospitals Network  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health The University of Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2280-8412","authenticated-orcid":false,"given":"Brendan","family":"Toy","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Launceston General Hospital  Launceston Tasmania Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-0101(99)00128-2"},{"key":"e_1_2_9_3_1","unstructured":"TGA.2.1 Amygdalin and Hydrocyanic Acid. Australian Government; 2021. Available from URL:https:\/\/www.tga.gov.au\/resources\/publication\/scheduling\u2010decisions\u2010interim\/notice\u2010interim\u2010decisions\u2010proposed\u2010amendments\u2010poisons\u2010standard\u2010acms\u2010accs\u2010and\u2010joint\u2010acms\u2010accs\u2010meetings\u2010november\u20102020\/21\u2010amygdalin\u2010and\u2010hydrocyanic\u2010acid."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4289527"},{"key":"e_1_2_9_5_1","article-title":"Laetrile treatment for cancer","volume":"2015","author":"Milazzo S","year":"2015","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Emergency Medicine Australasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1742-6723.14450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T02:37:26Z","timestamp":1721183846000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1742-6723.14450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":4,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/1742-6723.14450"],"URL":"https:\/\/doi.org\/10.1111\/1742-6723.14450","archive":["Portico"],"relation":{},"ISSN":["1742-6731","1742-6723"],"issn-type":[{"value":"1742-6731","type":"print"},{"value":"1742-6723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"2024-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}